FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mohamed Hatmi

Research Profile

Anatomy

Blood Platelets

Physiology

Chemicals & Drugs

Living Beings

Rabbits

Co-author Network

Publications

TOP 3
Asmae Karroum; Massoud Mirshahi; Pezhman Mirshahi; Amu Therwath; Anne-Marie Faussat; Mohamed Hatmi
Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions.
Grigoris Gerotziafas; Robert Girot; Mohamed Hatmi; Amir Khaterchi; François Lionnet; Micheline Maier-Redelsperger; Katice Stankovic-Stojanovic; van dreden patrick; Barry Woodhams; Olivier Blanc-Brude; Mourad Chaari; Vassiliki Galea; Ismail Elalamy
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Grigoris Gerotziafas; Mohamed Hatmi; Amir Khaterchi; Elisabeth Mbemba; Claudie Prengel; Mouna Sassi; van dreden patrick; Hela Baccouche; Jean François Bernaudin; Vassiliki Galea; Ismail Elalamy
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mohamed Hatmi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Asmae Karroum; Massoud Mirshahi; Pezhman Mirshahi; Amu Therwath; Anne-Marie Faussat; Mohamed Hatmi
Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions.
European journal of pharmacology 2012;685(1-3):1-7.
2012: Grigoris Gerotziafas; Robert Girot; Mohamed Hatmi; Amir Khaterchi; François Lionnet; Micheline Maier-Redelsperger; Katice Stankovic-Stojanovic; van dreden patrick; Barry Woodhams; Olivier Blanc-Brude; Mourad Chaari; Vassiliki Galea; Ismail Elalamy
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Thrombosis and haemostasis 2012;107(6):1044-52.
2012: Grigoris Gerotziafas; Mohamed Hatmi; Amir Khaterchi; Elisabeth Mbemba; Claudie Prengel; Mouna Sassi; van dreden patrick; Hela Baccouche; Jean François Bernaudin; Vassiliki Galea; Ismail Elalamy
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.
Thrombosis research 2012;129(6):779-86.
2011: Tahar Chakroun; Sadia Abdelkafi; Fatma Abderrezak; Faouzi Addad; Habib Gamra; Gregoris T Gerotziafas; Mohssen Hassine; Mohamed Hatmi; S Yacoub; Ismail Elalamy
The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients.
Genetic testing and molecular biomarkers 2011;15(7-8):513-6.
2010: Faouzi Addad; Ismail Elalamy; Tahar Chakroun; Fatma Abderrazek; Zohra Dridi; Sonia Hamdi; Mohssen Hassine; Mohamed Ben-Farhat; Grigoris Gerotziafas; Mohamed Hatmi; Habib Gamra
Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2010;21(7):674-8.
2010: Asmae Karroum; Pezhman Mirshahi; Nadia Benabbou; Anne-Marie Faussat; Jeannette Soria; Amu Therwath; Massoud Mirshahi; Mohamed Hatmi
Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways.
Cancer letters 2010;295(2):242-51.
2010: Faouzi Addad; Tahar Chakroun; Ismail Elalamy; Fatma Abderazek; Saoussen Chouchene; Zohra Dridi; Gregoris T Gerotziafas; Mohamed Hatmi; Mohsen Hassine; Habib Gamra
Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes.
International journal of hematology 2010;92(2):296-301.
2009: Grigoris Gerotziafas; charlotte dupont; Alex C Spyropoulos; Mohamed Hatmi; Meyer M Samama; Dimitris Kiskinis; Ismail Elalamy
Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
Thrombosis and haemostasis 2009;102(1):42-8.
2008: Grigoris T Gerotziafas; Chryssoula Papageorgiou; Mohamed Hatmi; Meyer-Michel Samama; Ismail Elalamy
Clinical studies with anticoagulants to improve survival in cancer patients.
Pathophysiology of haemostasis and thrombosis 2008;36(3-4):204-11.
2008: Anna D Petropoulou; Grigoris Gerotziafas; Meyer M Samama; Mohamed Hatmi; Francine Rendu; Ismail Elalamy
In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide.
Thrombosis research 2008;121(4):493-7.
2006: Tahar Chakroun; Grigoris Gerotziafas; Jerhad Seghatchian; Meyer M Samama; Mohamed Hatmi; Ismail Elalamy
The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile.
Thrombosis and haemostasis 2006;95(5):822-8.
2006: Ismail Elalamy; Mohamed Hatmi
Platelet function analyser-100 testing and primary haemostasis analysis.
British journal of haematology 2006;132(6):796-7; author reply 797-8.
2006: Mohamed Hatmi; Meyer M Samama; Ismail Elalamy
[Prevention of thrombosis and vascular inflammation: importance of combined cyclooxygenase and 5-lipoxygenase inhibitors].
Journal des maladies vasculaires 2006;31(1):4-9.
2004: Tahar Chakroun; Grigoris Gerotziafas; Françoise Robert; Chantal Lecrubier; Meyer M Samama; Mohamed Hatmi; Ismail Elalamy
In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor.
British journal of haematology 2004;124(1):80-5.
2003: Sameh Sarray; Najet Srairi; Mohamed Hatmi; José Luis; Hechmi Louzir; Imed Regaya; Hmida Slema; Jacques Marvaldi; Mohamed El Ayeb; Naziha Marrakchi
Lebecetin, a potent antiplatelet C-type lectin from Macrovipera lebetina venom.
Biochimica et biophysica acta 2003;1651(1-2):30-40.
2003: Fatima Ait-Said; Ismail Elalamy; Catherine Werts; Marie Thérèse Gomard; Claude Jacquemin; Jean-Paul Couetil; Mohamed Hatmi
Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway.
Biochimica et biophysica acta 2003;1631(1):77-84.
2002: Ismail Elalamy; Mohamed Hatmi
[What is the place of aspirin in venous thrombosis prophylaxis?].
Annales de cardiologie et d'angéiologie 2002;51(5):296-302.
2002: Fatima Ait Said; Catherine Werts; Ismail Elalamy; Jean-Paul Couetil; Claude Jacquemin; Mohamed Hatmi
TNF-alpha, inefficient by itself, potentiates IL-1beta-induced PGHS-2 expression in human pulmonary microvascular endothelial cells: requirement of NF-kappaB and p38 MAPK pathways.
British journal of pharmacology 2002;136(7):1005-14.
2000: I Kazes; Ismail Elalamy; Jean-Daniel Sraer; Mohamed Hatmi; Geneviève Nguyen
Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation.
Blood 2000;96(9):3064-9.
2000: Ismail Elalamy; F A Said; M Singer; Jean-Paul Couetil; Mohamed Hatmi
Inhibition by extracellular cAMP of phorbol 12-myristate 13-acetate-induced prostaglandin H synthase-2 expression in human pulmonary microvascular endothelial cells. Involvement of an ecto-protein kinase A activity.
The Journal of biological chemistry 2000;275(18):13662-7.
1998: S Emadi; Massoud Mirshahi; Ismail Elalamy; C Nicolas; B B Vargaftig; Mohamed Hatmi
Cellular source of human platelet secretory phospholipase A2.
British journal of haematology 1998;100(2):365-73.
1997: Ismail Elalamy; S Emadi; B B Vargaftig; Mohamed Hatmi
Signal transduction involved in the platelet adenylate cyclase sensitization associated with PGH2/TxA2 receptor desensitization.
British journal of haematology 1997;99(1):190-6.
1997: Ivo M B Francischetti; B Saliou; Mireille Leduc; Célia R Carlini; Mohamed Hatmi; J Randon; A Faili; Cassian Bon
Convulxin, a potent platelet-aggregating protein from Crotalus durissus terrificus venom, specifically binds to platelets.
Toxicon : official journal of the International Society on Toxinology 1997;35(8):1217-28.
1997: M Abdelouahed; Mohamed Hatmi; Gérard Helft; S Emadi; Ismail Elalamy; Meyer M Samama
Comparative effects of recombinant staphylokinase and streptokinase on platelet aggregation.
Thrombosis and haemostasis 1997;77(5):815-7.
1997: M Abdelouahed; Ismail Elalamy; Meyer M Samama; Mohamed Hatmi
Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets.
Thrombosis research 1997;86(3):255-62.
1996: Mohamed Hatmi; JM Gavaret; Ismail Elalamy; B Boris Vargaftig; C Jacquemin
Evidence for cAMP-dependent platelet ectoprotein kinase activity that phosphorylates platelet glycoprotein IV (CD36).
The Journal of biological chemistry 1996;271(40):24776-80.
1996: S Emadi; Ismail Elalamy; B Boris Vargaftig; Mohamed Hatmi
Reversible inhibition by protamine of human synovial and rabbit platelet secretory phospholipase A2.
Biochimica et biophysica acta 1996;1300(3):226-32.
1994: A Faili; S Emadi; B Boris Vargaftig; Mohamed Hatmi
Dissociation between the phospholipases C and A2 activities in stimulated platelets and their involvement in the arachidonic acid liberation.
British journal of haematology 1994;88(1):149-55.
1994: A Faili; J Randon; Ivo M B Francischetti; B Boris Vargaftig; Mohamed Hatmi
Convulxin-induced platelet aggregation is accompanied by a powerful activation of the phospholipase C pathway.
The Biochemical journal 1994;298 ( Pt 1)():87-91.
1993: Carine M Mounier; A Faili; B Boris Vargaftig; Cassian Bon; Mohamed Hatmi
Secretory phospholipase A2 is not required for arachidonic acid liberation during platelet activation.
European journal of biochemistry / FEBS 1993;216(1):169-75.
1993: A Faili; J Randon; B Boris Vargaftig; Mohamed Hatmi
Reduction by arachidonic acid of prostaglandin I2-induced cyclic AMP formation. Involvement of prostaglandins E2 and F2 alpha.
Biochemical pharmacology 1993;45(9):1815-20.
1993: S Desquand; Claude Ruffié; Jean Lefort; Mohamed Hatmi; M Pina; J G Priego; B Boris Vargaftig
Compound PCA-4248 interferes with bronchopulmonary anaphylaxis and with in vitro hyperresponsiveness to platelet-activating factor.
European journal of pharmacology 1993;235(1):101-8.
1993: Carine M Mounier; Mohamed Hatmi; A Faili; Cassian Bon; B Boris Vargaftig
Competitive inhibition of phospholipase A2 activity by the platelet-activating factor antagonist Ro 19-3704 and evidence for a novel suppressive effect on platelet activation.
The Journal of pharmacology and experimental therapeutics 1993;264(3):1460-7.
1993: Mohamed Hatmi; J Randon; A Faili; B Boris Vargaftig
Carrageenan-induced activation of human platelets is dependent on the phospholipase C pathway.
British journal of haematology 1993;83(2):270-5.
1992: Mohamed Hatmi; Nathalie Havet; B Boris Vargaftig; Maria Bachelet
Azelastine potentiates the prostaglandin-induced increase of cyclic AMP content in human platelets and in guinea-pig alveolar macrophages.
Prostaglandins 1992;43(5):457-72.
1991: Mohamed Hatmi; B Haye; JM Gavaret; B Boris Vargaftig; C Jacquemin
Alkaline phosphatase prevents platelet stimulation by thromboxane-mimetics.
British journal of pharmacology 1991;104(2):554-8.
1988: Mohamed Hatmi; J P Lussiana; J L Junien; J Burke; B Boris Vargaftig
Interference of eicosapentaenoic and docosahexaenoic acids with arachidonate-and U46619-induced platelet activation and desensitization.
Biochemical pharmacology 1988;37(3):481-9.
1988: Marcia Coronha Ramos Lima; Mohamed Hatmi; M A Martins; P M R Silva; E Malanchère; R N Cordeiro; B Boris Vargaftig
Mediators of inflammation and antagonism of experimental pleurisy in the rat by fenspiride.
Rhinology. Supplement 1988;4():85-92.
1987: B Vargaftig; D Joseph; Mohamed Hatmi
Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171.
Thrombosis research 1987;46(4):509-17.
1986: Mohamed Hatmi; D Rotilio; B Haye; F Antonicelli; D Joseph; B B Vargaftig
Modulation by cyclic AMP of arachidonic acid-induced platelet desensitization.
European journal of pharmacology 1986;132(2-3):219-28.
1985: L G Carmo; Mohamed Hatmi; D Rotilio; B B Vargaftig
Platelet desensitization induced by arachidonic acid is not due to cyclo-oxygenase inactivation and involves the endoperoxide receptor.
British journal of pharmacology 1985;85(4):849-59.
1984: D Rotilio; D Joseph; Mohamed Hatmi; B B Vargaftig
Structural requirements for preventing the aspirin- and the arachidonate-induced inactivation of platelet cyclo-oxygenase: additional evidence for distinct enzymatic sites.
European journal of pharmacology 1984;97(3-4):197-208.